Argent Advisors’s Charles River Laboratories CRL Stock Holding History

Argent Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5	Closed	–	–	201
2019 Q4	$0	Buy	+5	New	+$692	﹤0.01%	504

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Argent Advisors's CRL Position: Q1 2020 in Review

Argent Advisors sold out of Charles River Laboratories (CRL) in Q1 2020, closing a stake of 5 shares.

Argent Advisors first reported a position in CRL in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 414 funds tracked by Wall St. Rank hold CRL as of Q1 2020.

Argent Advisors reported no remaining Charles River Laboratories position as of Q1 2020 after selling out during the quarter.
Argent Advisors sold 5 Charles River Laboratories shares in Q1 2020.
Argent Advisors first reported a position in Charles River Laboratories in Q4 2019 and held it in 1 quarter.
Argent Advisors's Charles River Laboratories position peaked at $0 in Q4 2019.
414 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2020.

Based on Argent Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.